10/30/2026
New Implantable Glucose Monitor Could Eliminate the Need for External Wearable Devices
Continuous glucose monitoring technology could be approaching a major advancement that makes managing diabetes less intrusive.
Medical technology company has begun its first human clinical study of Freedom, an experimental glucose monitoring system designed to operate without an external transmitter attached to the body.
Most continuous glucose monitors require a sensor and an external component that communicates with a smartphone or monitoring device.
Senseonics is developing a different approach.
Its Freedom system uses an implanted sensor designed to communicate directly with a smartphone through Bluetooth, potentially eliminating the need to wear an external transmitter.
The technology is also being developed for up to one year of continuous glucose monitoring, which could significantly reduce the frequency of sensor replacements.
For people managing diabetes, this could mean fewer wearable components, less maintenance and a more convenient way to monitor glucose levels throughout the day.
The company has already completed preliminary testing and is now evaluating the system's safety and functionality in humans.
Senseonics expects to begin a larger clinical study in 2027, with a potential commercial launch targeted for 2028, subject to successful development and regulatory review.
The broader trend in medical technology is toward smaller, longer-lasting devices that collect important health information while requiring less daily interaction.
NAMICS Corporation